Your browser doesn't support javascript.
loading
Ligand-dependent kinase activity of MERTK drives efferocytosis in human iPSC-derived macrophages.
Wanke, Florian; Gutbier, Simon; Rümmelin, Anna; Steinberg, Malte; Hughes, Lindsey D; Koenen, Mascha; Komuczki, Juliana; Regan-Komito, Daniel; Wagage, Sagie; Hesselmann, Julia; Thoma, Ralf; Brugger, Doris; Christopeit, Tony; Wang, Hayian; Point, Floriane; Hallet, Remy; Ghosh, Sourav; Rothlin, Carla V; Patsch, Christoph; Geering, Barbara.
Afiliación
  • Wanke F; Immunology, Infectious Diseases and Ophthalmology (I2O) Discovery and Translational Area, Roche Innovation Center, Basel, Switzerland. florian.wanke@roche.com.
  • Gutbier S; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center, Basel, Switzerland.
  • Rümmelin A; Immunology, Infectious Diseases and Ophthalmology (I2O) Discovery and Translational Area, Roche Innovation Center, Basel, Switzerland.
  • Steinberg M; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center, Basel, Switzerland.
  • Hughes LD; Immunology, Infectious Diseases and Ophthalmology (I2O) Discovery and Translational Area, Roche Innovation Center, Basel, Switzerland.
  • Koenen M; Yale School of Medicine, Department for Immunobiology, Yale University, New Haven, Connecticut, USA.
  • Komuczki J; Yale School of Medicine, Department for Immunobiology, Yale University, New Haven, Connecticut, USA.
  • Regan-Komito D; Laboratory of Molecular Metabolism, Rockefeller University, New York, New York, USA.
  • Wagage S; Immunology, Infectious Diseases and Ophthalmology (I2O) Discovery and Translational Area, Roche Innovation Center, Basel, Switzerland.
  • Hesselmann J; Immunology, Infectious Diseases and Ophthalmology (I2O) Discovery and Translational Area, Roche Innovation Center, Basel, Switzerland.
  • Thoma R; Yale School of Medicine, Department for Immunobiology, Yale University, New Haven, Connecticut, USA.
  • Brugger D; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center, Basel, Switzerland.
  • Christopeit T; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center, Basel, Switzerland.
  • Wang H; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center, Basel, Switzerland.
  • Point F; Roche Pharma Research and Early Development, Roche Innovation Center München, Penzberg, Germany.
  • Hallet R; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center, Basel, Switzerland.
  • Ghosh S; Immunology, Infectious Diseases and Ophthalmology (I2O) Discovery and Translational Area, Roche Innovation Center, Basel, Switzerland.
  • Rothlin CV; Immunology, Infectious Diseases and Ophthalmology (I2O) Discovery and Translational Area, Roche Innovation Center, Basel, Switzerland.
  • Patsch C; Yale School of Medicine, Department for Neurology, Yale University, New Haven, Connecticut, USA.
  • Geering B; Yale School of Medicine, Department for Pharmacology, Yale University, New Haven, Connecticut, USA.
Cell Death Dis ; 12(6): 538, 2021 05 25.
Article en En | MEDLINE | ID: mdl-34035216
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fagocitosis / Tirosina Quinasa c-Mer / Macrófagos Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Cell Death Dis Año: 2021 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fagocitosis / Tirosina Quinasa c-Mer / Macrófagos Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Cell Death Dis Año: 2021 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Reino Unido